Luis Lara-Mejía: Neoadjuvant aumolertinib converted 45.1% of unresectable stage III EGFRm NSCLC to resectable status
Luis Lara-Mejía, Medical Oncologist Specialized in Thoracic Neoplasms at National Institute of Cancerology, shared on X about a recent paper shared by Dongliang Bian et al. in Nature Communications.
“In the LungMate-007 trial (NCT04685070), neoadjuvant aumolertinib converted 45.1% of unresectable stage III EGFRm NSCLC to resectable status.
- Objective response rate: 70.6%
- R0 resection: 100%
- Pathological complete response: 13.0%
- Duration: Median of 4 cycles (range: 2–6)
Neoadjuvant therapy durations have varied across studies:
- NEOS: 6 weeks of osimertinib.
- EMERGING-CTONG 1103: 42 days of erlotinib.
- ASCENT: 2 months of afatinib.
Determining the optimal duration is crucial to balance efficacy and timely surgery.
Integrating chemotherapy into the neoadjuvant treatment of resectable EGFR-mutant NSCLC is an area of active investigation. The NeoADAURA trial exemplifies this approach by comparing neoadjuvant osimertinib alone versus osimertinib combined with chemotherapy, versus chemotherapy alone, in patients with resectable stage II-IIIB N2 EGFR-mutant NSCLC.
Recent studies in advanced NSCLC indicate that combining EGFR-TKIs with chemotherapy can significantly improve progression-free survival compared to EGFR-TKI monotherapy. This approach may enhance tumor shrinkage and more effectively eliminate micrometastases than either modality alone.”
Authors: Dongliang Bian et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023